-
UPDATE: Piper Jaffray Raises PT on Orthofix to $37 (OFIX)
Wednesday, February 16, 2011 - 11:39am | 98Piper Jaffray is out with its report today on Orthofix (NASDAQ: OFIX), raising its PT from $35 to $37. In a note to clients, Piper Jaffray writes, "We rate OFIX Neutral and are raising our PT to $37, from $35, based on 2012E EBITDA of $121 mil (prev. $116 mil) and a multiple of 6.5x (unchanged)....
-
Benzinga's Volume Movers (GENZ, ELOS, KNXA, DELL)
Wednesday, February 16, 2011 - 11:32am | 165Genzyme Corporation (NASDAQ: GENZ) shares moved up 1.57% to $75.47 at 10:30 am. The volume of GENZ shares traded was 1854% higher than normal. Sanofi-Aventis SA (NYSE: SNY) has agreed to purchase GENZ for around $20.1 billion in cash. Syneron Medical Ltd (NASDAQ: ELOS) shares rose 17.72% to $13.75...
-
PRE-MARKET MOVERS:(PLAB),(ELOS),(AEIS),(CENX)
Wednesday, February 16, 2011 - 10:01am | 34PRE-MARKET MOVERS:(PLAB),(ELOS),(AEIS),(CENX)..
-
AMMD's 4Q EPS In-Line With Pre-Announcement, Piper Jaffray Maintains Neutral
Wednesday, February 16, 2011 - 9:54am | 118Piper Jaffray has published a research report on American Medical Systems (NASDAQ: AMMD) after the company reported 4Q EPS in-line with its pre-release estimates. In the report, Piper Jaffray writes "AMMD reported Q4 in line with its revenue pre-release and essentially no surprises on earnings or...
-
AtriCure Reports Q4 EPS of $0.00 vs. $(0.08)
Wednesday, February 16, 2011 - 9:39am | 40AtriCure, Inc. (Nasdaq: ATRC) today announced record financial results. Revenue was $16.4 million, reflecting a new high and 20.1 percent growth on a constant currency basis over the fourth quarter of 2009. Net income $ 11,544 EPS $0.00
-
Piper Jaffray Raises PT On Orthofix To $37
Wednesday, February 16, 2011 - 9:28am | 27Piper Jaffray has raised the price target on Orthofix International (NASDAQ: OFIX) from $35 to $37 and maintains its Neutral rating.
-
J.P Morgan Comments On St. Jude's Cardio Opportunities
Wednesday, February 16, 2011 - 8:33am | 192St. Jude's (NYSE: STJ) CardioMEMS is focused on developing novel technologies for the wireless transmission of vital information from within the human body. By increasing the accessibility of this data, the company hopes to improve the management of patients with chronic conditions and delay...
-
Jefferies Lowers PT On Orthofix To $35
Wednesday, February 16, 2011 - 8:23am | 27Jefferies & Company has lowered the price target on Orthofix International (NASDAQ: OFIX) from $36 to $35 and maintains its Buy rating.
-
Jefferies Raising Price Target On Insulet Corp (PODD)
Wednesday, February 16, 2011 - 8:23am | 90Jefferies & Co. is raising its price target on shares of Insulet Corp (NASDAQ: PODD) to $20 from $19, and has a Buy rating on shares. In a note to clients, Jefferies writes, "Insulet reported solid 4Q results this evening with revenues of $27.8mn matching forecasts. The company updated the...
-
JMP Securities Downs PODD To Market Perform
Wednesday, February 16, 2011 - 7:50am | 41Analysts at JMP Securities downgrade Insulet Corporation (NASDAQ: PODD) from “outperform” to “market perform.” PODD shares fell 1.18% to close at $17.64 yesterday. More Analyst Ratings here
-
Jefferies Raises PT On Insulet Corporation To $20
Wednesday, February 16, 2011 - 7:39am | 27Jefferies & Company has raised the price target on Insulet Corporation (NASDAQ: PODD) from $19 to $20 and maintains its Buy rating.
-
Mad Money Lightning Round OT: Cramer Likes FTNT (FTNT, CLDA, QLIK)
Tuesday, February 15, 2011 - 9:00pm | 188On CNBC's Mad Money Lightning Round OT, Jim Cramer said that he likes Fortinet, Inc. (NASDAQ: FTNT). He also said that he likes internet security, and that these stocks are red hot. Fortinet, Inc. (FTNT) fell 1.32% today, and closed at $40.46. Cramer thinks that Clinical Data, Inc. (NASDAQ: CLDA)...
-
Beckman Coulter's Board Recommends Stockholders Accept Danaher's Cash Tender Offer
Tuesday, February 15, 2011 - 5:38pm | 55Beckman Coulter, Inc. (NYSE: BEC) announced today that its board of directors unanimously recommends that Beckman Coulter's stockholders tender their shares to Danaher Corporation (NYSE: DHR) at the previously announced price of $83.50 per share of Beckman Coulter's common stock.
-
Gen-Probe Reports Q4 EPS of $0.61 vs. $0.55
Tuesday, February 15, 2011 - 5:27pm | 44Gen-Probe Incorporated (Nasdaq: GPRO) today reported financial results for the fourth quarter and full year 2010, highlighted by record non-GAAP earnings per share of $0.61 in the quarter, 17% higher than in the prior year period. Total revenues $136.7M
-
Gen-Probe Announces $150M Stock Repurchase Plan
Tuesday, February 15, 2011 - 5:26pm | 36Gen-Probe Incorporated (Nasdaq: GPRO) announced today that its board of directors has authorized the repurchase of up to $150 million of the Company's common stock over the next year.